- Home
- INSW vs VCEL Comparison
INSW vs VCEL Comparison
Compare INSW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- VCEL
- Stock Information
- Founded
- INSW 1999
- VCEL 1989
- Country
- INSW United States
- VCEL United States
- Employees
- INSW N/A
- VCEL N/A
- Industry
- INSW Semiconductors
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INSW Technology
- VCEL Health Care
- Exchange
- INSW Nasdaq
- VCEL Nasdaq
- Market Cap
- INSW 2.3B
- VCEL 2.1B
- IPO Year
- INSW N/A
- VCEL 1997
- Fundamental
- Price
- INSW $49.13
- VCEL $31.42
- Analyst Decision
- INSW Buy
- VCEL Strong Buy
- Analyst Count
- INSW 2
- VCEL 6
- Target Price
- INSW $52.00
- VCEL $61.50
- AVG Volume (30 Days)
- INSW 494.8K
- VCEL 677.8K
- Earning Date
- INSW 11-06-2025
- VCEL 11-06-2025
- Dividend Yield
- INSW 6.63%
- VCEL N/A
- EPS Growth
- INSW N/A
- VCEL 2045.40
- EPS
- INSW 4.81
- VCEL 0.13
- Revenue
- INSW $798,838,000.00
- VCEL $249,119,000.00
- Revenue This Year
- INSW N/A
- VCEL $18.35
- Revenue Next Year
- INSW $6.50
- VCEL $22.47
- P/E Ratio
- INSW $10.25
- VCEL $234.59
- Revenue Growth
- INSW N/A
- VCEL 16.13
- 52 Week Low
- INSW $27.20
- VCEL $30.26
- 52 Week High
- INSW $54.84
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- INSW 72.63
- VCEL 36.46
- Support Level
- INSW $45.76
- VCEL $30.26
- Resistance Level
- INSW $48.00
- VCEL $33.92
- Average True Range (ATR)
- INSW 1.08
- VCEL 1.52
- MACD
- INSW 0.15
- VCEL -0.22
- Stochastic Oscillator
- INSW 88.87
- VCEL 17.55
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.